The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma.
Auteurs
Bertucci F, De Nonneville A, Finetti P, Perrot D, Nilbert M, Italiano A, Le Cesne A, Skubitz KM, Blay JY, Birnbaum D
Résumé
Soft-tissue sarcomas (STSs) are a group of rare, heterogeneous, and aggressive tumors, with high metastatic risk and relatively few efficient systemic therapies. We hypothesized that the Genomic Grade Index (GGI), a 108-gene signature previously developed in early-stage breast cancer, might improve the prognostic assessment of patients with early-stage STS.
Lire l‘article